New study results suggest better outcomes with the CYPHER® Stent than brachytherapy

October 17, 2005

WASHINGTON, D.C. - (October 17, 2005) - Results from the SISR trial, a multi-center, randomized study of the CYPHER(r) Sirolimus-eluting Coronary Stent versus radiation from within a vessel (brachytherapy) in patients with bare-metal in-stent reblockage (restenosis), were presented today at the Transcatheter Cardiovascular Therapeutics (TCT).

2005) Scientific Symposium. The study showed that patients who received the CYPHER(r) Stent had a significantly lower incidence of target vessel failure (TVF) at nine months post-procedure compared with patients who received brachytherapy. The SISR trial was sponsored by Cordis Corporation, a Johnson & Johnson company.

"The efficacy and safety results from this study were significantly better in the drug-eluting stent arm of the study," said Principal Investigator David R. Holmes, Jr., M.D., Professor of Medicine at the Mayo Clinic College of Medicine. "The CYPHER(r) Stent has shown excellent results in complex patient cases and this is another example of a strong clinical performance in a category that has challenged physicians for years."

A large, multicenter, randomized study involving 384 patients, the Sirolimus-eluting CYPHER(r) Stent Versus Intravascular Brachytherapy In the Treatment of Patients with In-Stent Restenotic Coronary Artery Lesions, or SISR trial, showed the superior safety profile of the

CYPHER(r) Stent compared to intravascular brachytherapy in complex patients. The primary endpoint of the study was the incidence of TVF, defined as cardiac death, heart attack (myocardial infarction), or the need to re-open the artery (target vessel revascularization, or TVR) at nine months.

Nine-Month Events Target vessel failure MACE Target lesion revascularization The nine-month results of the SISR data were highlighted today in a late-breaking session at TCT, highlighted by Dr. Holmes and moderated by Martin B. Leon, M.D., and Patrick W. Serruys, M.D. The results revealed that the CYPHER(r) Stent resulted in fewer Major Adverse Cardiac Events (MACE), including death, heart attack and stroke at nine-month follow-up (10.0 percent compared to 19.2 percent; p=0.015) by significantly decreasing the need for TLR procedures (8.5 percent versus 19.2 percent; p=0.004).

"The results from the data presented today at TCT continue to build on our body of evidence for treating complex patients," said Brian Firth, M.D., Ph.D., Vice President of Medical Affairs and Health Economics, Cordis Corporation. "It is necessary to provide a treatment option that is safe and effective and the CYPHER Stent continues to demonstrate excellent outcomes in clinical trials and in the real world."
-end-
Information on all of the CYPHER(r) Stent-related studies being presented at TCT 2005 can be found at www.tct2005.com .

About the CYPHER(r) Stent
The CYPHER(r) Stent has been chosen by cardiologists worldwide to treat more than 1.5 million patients with coronary artery disease. It is supported by a robust clinical trial program, which includes more than 40 studies examining its performance in vessels of varying complexity.

Developed and manufactured by Cordis Corporation, the CYPHER(r) Stent is currently available in 80 countries. CYPHER SELECT(tm) Sirolimus-eluting Coronary Stent, which is the first next generation drug-eluting stent, was launched in Europe, Asia Pacific, Latin America and Canada in 2003.

More information about the CYPHER(r) Stent can be found at www.cypherusa.com .

About Cordis Corporation
Cordis Corporation, a Johnson & Johnson company, is a worldwide leader in developing and manufacturing interventional vascular technology.

Through the company's innovation, research and development, physicians worldwide are better able to treat the millions of patients who suffer from vascular disease.

*Cordis Corporation has entered into an exclusive worldwide license with Wyeth for the localized delivery of sirolimus in certain fields of use, including delivery via vascular stenting. Sirolimus, the active drug released for the stent, is marketed by Wyeth Pharmaceuticals, a division of Wyeth, under the name Rapamune(r). Rapamune is a trademark of Wyeth Pharmaceuticals.

Edelman Public Relations

Related Heart Attack Articles from Brightsurf:

Top Science Tip Sheet on heart failure, heart muscle cells, heart attack and atrial fibrillation results
Newly discovered pathway may have potential for treating heart failure - New research model helps predict heart muscle cells' impact on heart function after injury - New mass spectrometry approach generates libraries of glycans in human heart tissue - Understanding heart damage after heart attack and treatment may provide clues for prevention - Understanding atrial fibrillation's effects on heart cells may help find treatments - New research may lead to therapy for heart failure caused by ICI cancer medication

Molecular imaging identifies link between heart and kidney inflammation after heart attack
Whole body positron emission tomography (PET) has, for the first time, illustrated the existence of inter-organ communication between the heart and kidneys via the immune system following acute myocardial infarction.

Muscle protein abundant in the heart plays key role in blood clotting during heart attack
A prevalent heart protein known as cardiac myosin, which is released into the body when a person suffers a heart attack, can cause blood to thicken or clot--worsening damage to heart tissue, a new study shows.

New target identified for repairing the heart after heart attack
An immune cell is shown for the first time to be involved in creating the scar that repairs the heart after damage.

Heart cells respond to heart attack and increase the chance of survival
The heart of humans and mice does not completely recover after a heart attack.

A simple method to improve heart-attack repair using stem cell-derived heart muscle cells
The heart cannot regenerate muscle after a heart attack, and this can lead to lethal heart failure.

Mount Sinai discovers placental stem cells that can regenerate heart after heart attack
Study identifies new stem cell type that can significantly improve cardiac function.

Fixing a broken heart: Exploring new ways to heal damage after a heart attack
The days immediately following a heart attack are critical for survivors' longevity and long-term healing of tissue.

Heart patch could limit muscle damage in heart attack aftermath
Guided by computer simulations, an international team of researchers has developed an adhesive patch that can provide support for damaged heart tissue, potentially reducing the stretching of heart muscle that's common after a heart attack.

How the heart sends an SOS signal to bone marrow cells after a heart attack
Exosomes are key to the SOS signal that the heart muscle sends out after a heart attack.

Read More: Heart Attack News and Heart Attack Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.